long intergenic non-protein coding RNA 659Genealiases: []
Q-omics provides the consensus-scored LINC00659 profile across patient tissues and cancer cell-line models. LINC00659 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC00659 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, LINC00659 RNA expression shows 11,436 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, COAD, and ESCA as cancer lineages where LINC00659 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00659 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00659 survival associations across molecular data types. LINC00659 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00659 RNA expression–survival associations across cancer types. High LINC00659 expression shows unfavorable associations in ACC, OV and HNSC, but favorable associations in KIRC, CESC and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC00659 RNA expression.
This table summarizes LINC00659 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00659. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00659 shows lower tumor expression in THCA and higher tumor expression in COAD, HNSC, READ, STAD and BRCA. The COAD box plot shows higher LINC00659 RNA expression in tumor versus normal tissue (log2 FC = +2.865, t-test p < 0.001).
This table shows molecular features associated with LINC00659 in patient tissues and cancer cell lines. In patient samples, LINC00659 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
